Almanac of Clinical MedicineAlmanac of Clinical Medicine2072-05052587-9294Moscow Regional Research and Clinical Institute (MONIKI)2610.18786/2072-0505-2013-29-23-28EFFECT OF METFORMIN AND PYOGLITAZON ON THE RISK FACTORS OF CARDIOVASCULAR PATHOLOGY DIAGNOSED DURING SCREENING OF PATIENTS WITH TYPE 2 DIABETES MELLITUSMisnikovaI. V.fake@neicon.ruDrevalA. V.fake@neicon.ruLakeevaT. S.fake@neicon.ruM.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)151020132923281102201611022016Copyright © 2013, Misnikova I.V., Dreval A.V., Lakeeva T.S.2013<p>Under assessment there was metformin and pyoglitazon effect on the risk factors of cardiovascular disease. During treatment of patients with screening-diagnosed type 2 diabetes mellitus, the following changes were noted: decreasing the levels of glycated hemoglobin, Willebrand factor and C-reactive protein, and increasing the level of HDL cholesterol. It was shown that 6-month-long therapy with metformin and pyoglItazon allowed significant improving glycemia control and influencing markers of cardiovascular risk in these patients.</p>cardiovascular disease riskWillebrand factorС-reactive proteinсердечно-сосудистый рискфактор ВиллебрандаС-реактивный белок[1.Древаль А.В., Мисникова И.В., Барсуков И.А. Лечение ранних нарушений углеводного обмена // Леч. врач. 2008. №10. С.36-39.][2.Мисникова И.В., Древаль А.В., Ковалева Ю.А. Риски общей и сердечно-сосудистой смертности, а также инфаркта миокарда и острого нарушения мозгового кровообращения у больных сахарным диабетом 2 типа в зависимости от вида стартовой сахароснижающей терапии // Сахарный диабет. 2009. №4. С.72-76.][3.Мкртумян А.М., Аметов А.С., Суркова Е.В. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под ред. И.И. Дедова, М.В. Шестаковой // Cахарный диабет. 2011. №3. Приложение.][4.DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria // Arch. Intern. Med. 2001. V.161. P.397-405.][5.Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Geneva: WHO, 1999. 46 p.][6.Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study // Lancet. 2009. V.374. P.1677-1686.][7.Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin // N. Engl. J. Med. 2002. V.346. P.393-403.][8.Gore O., McGuire D. The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context // Diab. Vasc. Dis. Res. 2009. V.6. P.53.][9.International Diabetes Federation. Global Guideline for Type 2 Diabetes. 2005. P.35-36.][10.International Diabetes Federation. The Diabetes Atlas. 3th ed. 2006; 4th ed. 2009.][11.Inzucchi S.E., Bergenstahl R.M., Buse J.B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach // Diabetes Care. 2012. V.35.][12.Nathan D.M., Buse J.B., Davidson M.B. et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy // Diabetes Care. 2009. V.31. P.1-11.][13.Qiao Q., Lindstrom J., Valle T. et al. Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycemia // Diabet Med. 2003. V.20. P.1027-1033.][14.Selvin E., Steffes M.W., Zhu H. et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults // N. Engl. J. Med. 2010. V.362, No.9. P.800-811.][15.Тuomilehto J., Lindstrom J., Eriksson J. et al. Prevention on type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance // N. Engl. J. Med. 2001. V.344. P.1343-1350.]